Veterinary Infectious Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Veterinary Infectious Disease Diagnostics Market is projected to expand from USD 1.61 Billion in 2025 to USD 2.19 Billion by 2031, reflecting a compound annual growth rate of 5.26%. This sector encompasses a variety of laboratory instruments, reagents, and immunodiagnostic kits essential for detecting bacterial, viral, and parasitic pathogens in livestock and companion animals.

Key drivers propelling this growth include the rising prevalence of transboundary zoonotic diseases and the economic imperative to ensure global food security through effective herd health management. Additionally, the trend of pet humanization has increased owner willingness to fund advanced healthcare, thereby stimulating demand for rapid and precise pathogen detection. The urgency of this demand is highlighted by World Organisation for Animal Health data, which recorded 14,918 outbreaks of African swine fever and 6,346 outbreaks of high pathogenicity avian influenza between January 2024 and May 2025.

Despite these strong growth drivers, the market encounters significant obstacles due to the high acquisition and operational costs associated with advanced molecular diagnostic technologies. These financial constraints frequently limit the adoption of precise testing methods in developing regions where veterinary budgets are restricted and agricultural sectors remain price-sensitive. Consequently, this economic barrier hampers the widespread deployment of state-of-the-art diagnostics in areas where many infectious outbreaks originate, creating a substantial impediment to the uniform expansion of the global market.

Market Drivers

The escalating prevalence of transboundary and zoonotic animal diseases serves as a primary engine for market expansion, necessitating that governments and agricultural bodies prioritize rigorous surveillance systems to ensure food security. This focus on biosecurity accelerates the procurement of advanced diagnostic reagents and instruments capable of rapid pathogen identification in livestock. To address these vulnerabilities, significant financial resources are being allocated to strengthen detection infrastructure. For instance, the U.S. Department of Agriculture announced in May 2024 that it awarded over $22.2 million in Farm Bill funding to 81 projects aimed at enhancing early detection and rapid response capabilities for threatening animal diseases, directly subsidizing the adoption of diagnostic technologies to mitigate economic losses.

Simultaneously, the rising adoption of companion animals and the phenomenon of pet humanization are fundamentally altering the veterinary services landscape, leading to increased expenditure on diagnostic and preventative healthcare. As owners increasingly view pets as family members, their willingness to pay for sophisticated medical testing has grown, incentivizing clinics to upgrade their on-site testing capabilities. This trend is reflected in the American Pet Products Association's August 2024 report, which noted that total U.S. spending on veterinary care and products reached $39.8 billion in 2024. Leading industry players further evidence this demand; IDEXX Laboratories reported full-year 2024 revenues of $3.898 billion in 2025, underscoring the lucrative nature of the diagnostics sector driven by these dual market forces.

Market Challenges

The primary obstacle to market expansion is the prohibitive cost associated with acquiring and operating advanced molecular diagnostic technologies. These sophisticated testing platforms require substantial capital investment and rely on expensive reagents, creating a high barrier to entry for livestock producers and veterinary clinics with limited budgets. In price-sensitive agricultural sectors and developing regions, these financial demands often force practitioners to rely on traditional, less accurate methods rather than adopting modern diagnostic solutions, thereby stifling the market's potential reach in areas where infectious risks are frequently highest.

This economic strain is exacerbated by the broader escalating costs of animal healthcare, which limit the disposable income available for premium diagnostic services. According to the American Animal Hospital Association, the lifetime cost of care for a dog increased by 11.65% in 2025 compared to 2022 levels. Such rising expenses compel farmers and pet owners to scrutinize spending, often resulting in the rejection of high-cost diagnostic procedures in favor of basic symptomatic treatments. Consequently, this financial reticence directly hampers revenue growth and the widespread global adoption of advanced diagnostic tools.

Market Trends

The integration of Artificial Intelligence and Machine Learning into diagnostics is fundamentally reshaping veterinary practice by automating complex analytical tasks and improving diagnostic accuracy. This trend addresses the shortage of specialists by embedding deep learning algorithms into analyzers, allowing practitioners to obtain reference-quality interpretations for cytology and hematology in real-time. This technological leap is evidenced by recent advancements; in December 2024, Zoetis Inc. announced AI-driven updates to its Vetscan Imagyst platform, including a new algorithm capable of identifying and differentiating white blood cells within minutes, thereby streamlining the diagnostic workflow.

Concurrently, the adoption of Point-of-Care and Rapid Diagnostic Testing is shifting infectious disease management from central laboratories to the clinic, facilitating immediate pathogen detection. By utilizing on-site analyzers, veterinarians can rapidly implement biosecurity measures and treatment plans, a capability essential for controlling contagious outbreaks. The market's pivot toward these solutions is quantified by financial performance; IDEXX Laboratories, Inc. reported in October 2024 a 10% year-over-year growth in its global premium instrument installed base, underscoring the increasing investment by practices in rapid, in-house diagnostic infrastructure.

Key Players Profiled in the Veterinary Infectious Disease Diagnostics Market

• BIOMeRIEUX
• Heska Corporation
• Neogen Corporation
• INDICAL BIOSCIENCE GmbH
• Randox Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• Creative Diagnostics
• DRG INSTRUMENTS GMBH
• Chembio Diagnostic Systems, Inc.
• Eurofins Technologies
• Agrolabo S.p.A.
• Abbott Laboratories inc.
• Danaher Corporation

Report Scope

In this report, the Global Veterinary Infectious Disease Diagnostics Market has been segmented into the following categories:

Veterinary Infectious Disease Diagnostics Market, by Technology:

• Immunodiagnostics
• Molecular Diagnostics
• Other Veterinary Diagnostic Technologies

Veterinary Infectious Disease Diagnostics Market, by Animal Type:

• Companion Animals
• Food Producing Animals

Veterinary Infectious Disease Diagnostics Market, by End User:

• Reference Laboratories
• Veterinary Laboratories and Clinics
• Point of Care / In House Testing
• Research Institutes and Universities

Veterinary Infectious Disease Diagnostics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Infectious Disease Diagnostics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.